Logo

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Share this

M&A

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots:

  • Genentech to acquire Jecure- in all stock transaction for the portfolio of preclinical NLRP3 inhibitors
  • The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis
  • NLRP3 - Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3- investigated for the treatment of autoimmune and inflammatory disorders

Ref: Jecure Therapeutics | Image: Xconomy


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions